Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuationREMAIN-1 pivotal study now more than 50% enrolled; ...

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence Average Total Weight Loss of 20% With 15% ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Many employers are facing challenges in incorporating high-cost GLP-1 medications, such as Mounjaro, Ozempic, Rybelsus, Trulicity, and Wegovy, ...

Gallagher Re, a reinsurance brokerage and risk management services provider, has released a report on the impact of GLP-1 ...

Allurion Technologies (ALUR) announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize ...

Clinical Outcomes Among Commercially Insured Among individuals persistent to their GLP-1 therapy over two years, this study compares changes in clinical outcomes one year before, one year after ...

"It's an honor to be recognized with this award for our GLP-1 research as it validates that ... Analyzing Bevacizumab Persistence and Therapy Switching." Prime researchers will participate ...